Literature DB >> 21497842

Immediate unplanned hospital admission after outpatient ureteroscopy for stone disease.

Hung-Jui Tan1, Seth A Strope, Chang He, William W Roberts, Gary J Faerber, J Stuart Wolf.   

Abstract

PURPOSE: Medicare recently changed reimbursement for ureteroscopy, encouraging migration to ambulatory surgical centers. To our knowledge the risk of immediate unplanned hospital admission, which may discourage ureteroscopy at ambulatory surgical centers, is unknown. We determined the rate of immediate unplanned hospital admission, identified factors associated with admission and developed a risk stratification tool to assist with location selection for outpatient ureteroscopy.
MATERIALS AND METHODS: We retrospectively reviewed the records of 1,798 consecutive outpatient ureteroscopic procedures for urolithiasis performed from 1998 to 2008 at our institution. Patients requiring immediate hospital admission were matched 1 to 3 by provider, gender and date with controls who did not require admission. Patient demographics, comorbid conditions, stone history and burden, and operative technique were assessed for impact on admission by bivariate and multivariate logistic regression. A scoring system was developed and estimated admission rates were calculated.
RESULTS: There were 70 immediate unplanned admissions (3.9%). Based on multivariate analysis the factors associated with unplanned admission were any previous admission related to stones (p <0.001), history of psychiatric illness (p = 0.016) and bilateral procedure (p = 0.019). Patients with distal ureteral stones were less likely to require admission (p = 0.026). One point was added for each positive factor and 1 was subtracted for a distal ureteral stone. A risk factor score of 2 or greater in 9% of the cohort was associated with an estimated 20.0% admission rate while lower scores in 91% of the cohort were associated with a 2.9% admission rate.
CONCLUSIONS: Readily identifiable factors can stratify the risk of unplanned hospital admission and help guide the selection of the most appropriate facility for outpatient ureteroscopy.
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21497842     DOI: 10.1016/j.juro.2011.01.081

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

1.  New Persistent Opioid Use After Outpatient Ureteroscopy for Upper Tract Stone Treatment.

Authors:  Christopher A Tam; Casey A Dauw; Khurshid R Ghani; Vidhya Gunaseelan; Tae Kim; David A Leavitt; Jeremy Raisky; Phyllis L Yan; John M Hollingsworth
Journal:  Urology       Date:  2019-09-16       Impact factor: 2.649

2.  Acute postoperative pain after ureteroscopic removal of stone: incidence and risk factors.

Authors:  Sun Tae Ahn; Jae Heon Kim; Jae Young Park; Du Geon Moon; Jae Hyun Bae
Journal:  Korean J Urol       Date:  2012-01-25

3.  Opioid-Free Discharge is Not Associated With Increased Unplanned Healthcare Encounters After Ureteroscopy: Results From a Statewide Quality Improvement Collaborative.

Authors:  Scott R Hawken; Spencer C Hiller; Stephanie Daignault-Newton; Khurshid R Ghani; John M Hollingsworth; Bronson Conrado; Conrad Maitland; David L Wenzler; John K Ludlow; Sapan N Ambani; Chad M Brummett; Casey A Dauw
Journal:  Urology       Date:  2021-09-01       Impact factor: 2.649

4.  Results of day-case ureterorenoscopy (DC-URS) for stone disease: prospective outcomes over 4.5 years.

Authors:  Anngona Ghosh; Rachel Oliver; Carolyn Way; Lucy White; Bhaskar K Somani
Journal:  World J Urol       Date:  2017-06-15       Impact factor: 4.226

5.  Predicting procedural pain after ureteroscopy: does hydrodistention play a role?

Authors:  Zeynep Gul; Kareem Alazem; Ina Li; Manoj Monga
Journal:  Int Braz J Urol       Date:  2016 Jul-Aug       Impact factor: 1.541

6.  Flexible and rigid ureteroscopy in outpatient surgery.

Authors:  Abeni Oitchayomi; Arnaud Doerfler; Sophie Le Gal; Charles Chawhan; Xavier Tillou
Journal:  BMC Urol       Date:  2016-01-28       Impact factor: 2.264

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.